Disclosed herein are methods of administering an agent targeting a lineage-specific cell-surface antigen and a population of hematopoietic cells that are deficient in the lineage-specific cell-surface antigen for immunotherapy of hematological malignancies.

The present invention describes a method for treating cancer comprising adoptive transfer of tumor antigen specific CD8+ T cells and an oncolytic virus vaccine targeting the same antigen.

The present invention relates to an in vitro culture of haematopoietic cells, wherein said haematopoietic cells differentiate to form granulocytes characterised by the ability to kill cancer cells. The invention also relates to said granulocytes, methods for identifying said haematopoietic cells and granulocytes, compositions and kits comprising the same, as well as uses of the same for treating cancer.

This invention relates to methods for the expansion of T-lymphocytes with a memory-like phenotype in which the intracellular concentration of a memory induction compound, such as 2-hydroxyglutarate (2HG), is increased in order to facilitate the maintenance of a memory-like phenotype. This may be useful for example, in cellular immunotherapy. The memory induction compound may the formula (I) wherein: p is 0 or 1, and when p is 0, Y is CH.sub.2 or C?, and when p is 1, Y is selected from CH, CH.sub.2, NH, S, and -0-; R.sup.1 is H, (CH.sub.2).sub.nCH.sub.3, (CH.sub.2).sub.nCH.sub.2CO.sub.2H, CH.sub.2Ph or CH.sub.2PhOCH.sub.2Ph; and when Y is CH, CH.sub.2, NH, S, or O, X is a single bonded group selected from H, OH, NH.sub.2, SH, (CH.sub.2).sub.nCH.sub.3 (CH.sub.2).sub.nCH.sub.2CO.sub.2H, F, Cl, Br, and I, or a double bonded group selected from ?O and ?S; and when Y is a double bonded C?, X is H; and each n is independently 0 to 12.

##STR00001##

Materials and methods for producing genome-edited cells engineered to express a chimeric antigen receptor (CAR) construct on the cell surface, and materials and methods for genome editing to modulate the expression, function, or activity of one or more immuno-oncology related genes in a cell, and materials and methods for treating a patient using the genome-edited engineered cells.

Materials and methods for producing genome-edited cells engineered to express a chimeric antigen receptor (CAR) construct on the cell surface, and materials and methods for genome editing to modulate the expression, function, or activity of one or more immuno-oncology related genes in a cell, and materials and methods for treating a patient using the genome-edited engineered cells.

Disclosed herein are methods of administering an agent targeting a lineage-specific cell-surface antigen and a population of hematopoietic cells that are deficient in the lineage-specific cell-surface antigen for immunotherapy of hematological malignancies.

Disclosed herein are methods for treating cancer comprising administering CAR-modified immune cells and at least one Retinoic Acid Receptor agonist.

Provided herein are T-cell receptor (TCR) fusion proteins (TFPs), T-cells engineered to express one or more TFPs, and methods of use thereof for the treatment of diseases, including cancer.

Peptides that generate an immune response to glioma-related H3.3 proteins and methods of their use are provided.